Catherine Beech

Sage Healthcare Ltd. provides management consulting services to the healthcare industry. The firm's services include strategic analysis and development; mergers and acquisitions; business development, support, and planning; corporate partnering; licensing and venturing; technology and compound brokerage; valuations and value-enhancement planning; forecasting; risk assessment and due diligence; and commercial and technical assessment. The company was founded in 1995 and is headquartered in Great Shelford, GB.

CFA Society of the UK is an association of investment professionals based in the UK. The British company was founded in an unspecified year.

Exonate engages in the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. It develops SPHINXes, a pipeline of novel small molecule inhibitors. The company was founded by David Owen Bates, Lucy Donaldson, Steeven J. harper and Catherine Beech in 2013 and is headquartered in Nottingham, the United Kingdom.

Locate Bio Ltd. operates as a regenerative medicine development company. The firm focuses on clinical problems in which regeneration of human tissue will displace biomaterial or drug therapies. Its products are orthopaedic matrices with unique properties for hard to heal clinical applications. The company was founded by Robin Quirk and is headquartered in Nottingham, the United Kingdom.

O2h Ltd (O2h) is a venture capital firm. The firm is founded by Sunil and Prashant Shah. It is headquartered in United Kingdom.

PBL-Ventures is the business start-up and mentoring arm of Plant Bioscience Ltd founded in 1994. The firm is headquartered in the UK.

PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom.

Chameleon BioSurfaces is a provider of sophisticated surface design technology to medical device companies. Chameleon works closely with its customers to design and produce unique solutions to specific device challenges and opportunities. The company specialized in using electro-deposition to apply polymers to the surfaces of medical implants and devices to improve the functionality, performance and reliability of such systems. Its polymers can impart such features as lubricity, wettability, bio-compatibility and drug-elution. The company can design surfaces so that drugs have a desired elution profile over time or are retained and presented at the device surface. Also, it had unique patented technology to enable, for certain device configurations, on & off switching and extremely precise control of the amount, timing and location of drug release. Chameleon's patented polymer deposition methods offer many manufacturing and process advantages. Polymers can be deposited in discrete patterns and gradients as well as uniformly over a device surface. Multiple polymer layers, each with a different functionality, allow highly sophisticated design features. Its electro-deposition methods ensure complete coverage even of complex and intricate surfaces, and also afford exquisite control of coating thickness, from sub-micron level upwards.